Trial Profile

A Proof of Concept, Multi-centre, Clinical Trial of the Combination Cediranib-Olaparib at the Time of Disease Progression on PARP Inhibitor in Ovarian Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cediranib (Primary) ; Olaparib (Primary)
Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Proof of concept; Therapeutic Use
Acronyms e-Volve 1; Evolve

Most Recent Events

16 Jun 2023 Results of a cfDNA fragmentation analyses, evaluating cediranib plus olaparib after progression on PARPi alone using longitudinal cfDNA samples collected from 30 patients with HGSOC enrolled in this phase II clinical trial published in the Clinical Cancer Research
23 Jun 2022 Last checked against European Clinical Trials Database record.
03 May 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com